EP0946583A1 - Bissteroidal compounds and their use for the preparation of chiral complexes - Google Patents

Bissteroidal compounds and their use for the preparation of chiral complexes

Info

Publication number
EP0946583A1
EP0946583A1 EP97954819A EP97954819A EP0946583A1 EP 0946583 A1 EP0946583 A1 EP 0946583A1 EP 97954819 A EP97954819 A EP 97954819A EP 97954819 A EP97954819 A EP 97954819A EP 0946583 A1 EP0946583 A1 EP 0946583A1
Authority
EP
European Patent Office
Prior art keywords
stands
alkyl
hydrogen
aryl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97954819A
Other languages
German (de)
French (fr)
Inventor
Jörg-Torsten MOHR
Valentien Enev
Christian Ewers
Michael Harre
Klaus Hickisch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to EP97954819A priority Critical patent/EP0946583A1/en
Publication of EP0946583A1 publication Critical patent/EP0946583A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0055Estrane derivatives not substituted in position 17
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0066Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0077Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Definitions

  • the invention relates to bissteroidal compounds and their use for the preparation of chiral complexes, useful as catalysts for various asymmetric syntheses.
  • the present invention describes the diastereoselective synthesis of (Fta)- and (Sa)- 4,4'-bis(3-Diphenylphosphinoestra-1 ,3,5(10), 6, 8-pentaene) and the application of these new bisphosphines as chiral ligands in metal complexes for the enantioselective hydrogenation of ⁇ -ketoesters, ⁇ - ⁇ -unsaturated acids and dehydroaminoacids.
  • Detailed description of the invention are examples of the invention.
  • Rl stands for hydrogen, alkyl, acyl, fluorine, and X-1 R5, where X-
  • R2 stands for hydrogen and alkyl; the stereochemistry of C-13, C-14 and C-17 may either be a or b,
  • X stands for oxygen, hydroxyl, trifluormethylsulfonyloxy, or (R 6 ) 2 P, where Rg can be aryl, alkyl and cycloalkyl,
  • R3 stands for hydrogen, alkyl, aryl, trialkylsilyl, fluorine and X2R6.
  • X 2 stands for oxygen and sulfur and
  • Rg stands for hydrogen, trifluormethylsulfonyl, alkyl, cyloalkyl or aryl.
  • R4 can either be a substituent in the 6 or 7 position of the steroid with the meaning of hydrogen, alkyl, aryl, fluorine, and X3R7, where X3 stands for oxygen, sulfur or trialkylsilyl and R7 stands for hydrogen, trifluormethylsulfonyl, alkyl or aryl, and the B-ring of the steroid contains none or two double bonds.
  • the alkyl radical of Ri - R7 have the meaning of lower alkyl substituents, for example the methyl-, ethyl-, propyl-, 2-methylethyl-, 2-methyl-propyl-, 3-methyl-propyl-, 2,2- dimethyl-ethyl- or butyl group.
  • the acyl radical of Ri have the meaning of C1-C6- groups, per example acyl-, propionylic-, butyric or hexanoic group.
  • the aryl group radical of R3, R4, R$, Rg and R7 have the meaning of phenyl-, benzyl- or 4-methyl- phenyl substituents.
  • the cycloalkyl radical of Rg has the meaning of a cyclopentyl- or cyclohexyl group.
  • the trialkylsilyl radical of R3 or X3 have the meaning of trimethyl- or tert.-butyldimethylsilyl.
  • the targets (Ra)- and (Sa)-4,4'-bis(Estra-1 , 3,5(10),6,8-pentaen-3-ol) (bisequilenol) 3 are prepared from Estra-1 , 3,5(10) ,6, 8-pentaen-3-ol 2 via metal catalyzed phenolic coupling.
  • the coupling is performed with catalytic amounts of a copper-amine complex in methylenechloride under an oxygen atmosphere (Tetrahedron Lett. 1994, 35, 7983). generating the diastereomers S-3 and R-3.
  • the diastereoselectivity of the coupling shows a temperature dependance favouring the R-isomer at room temperature with a diasteromeric excess of 50%. At lower temperature the selectivity is inverted, favouring the S-isomer with almost the same diasteromeric excess (Table 1). In order to make both isomers available the coupling is performed at 0° C providing both diastereomers in a combined yield of 92-96%.
  • the absolute configuration of the reduction products is also the same as in the Noyori reduction. As expected the reduction with the two diasteromeric ligands R-3 and S-3 produce the opposite enantiomers of the reduction product.
  • the bissteroids R-/S-4 and R-/S-5 were prepared by copper mediated coupling
  • the catalysts R-Ti-1 and S-Ti-1 afford the product 3-Methoxyestra- 1 , 3,5(10),8,14-pentaene-17-one due to their diastereomeric nature with a different chemical and optical yield each.
  • the triflate 6 was then converted into the bisphoshine 7 without any isomerisation of the diastereomers in 83% yield.
  • epimeric phosphines Epi-R-7 and Epi-S-7 are available according to a similar synthetic sequence starting with 14-Epi-equilenine 14-Epi-1 (Tetrahedron Lett. 1971 ,
  • the new phosphines R-7 and S-7 were tested as chiral ligands in a ruthenium complex for the asymmetric hydrogenation of methyl-acetoacetate, N-acetyl-cinnamic acid and tiglic acid as representative examples (Table 3).
  • the chiral ruthenium complex is prepared by heating the bisphosphines R-/S-7 with [RuCI 2 (benzene)] 2 in DMF (Tetrahedron Lett. 1991 , 32, 4163).
  • the new chiral complexes synthesized from [RuCI 2 (benzene)] 2 and the bissteroidal ligands 7 are more powerful than the state-of-the-art BINAP-ruthenium complexes of Noyori as they are of broader applicability and allow the preparation of a range of substrates of extraordinary high enantiomeric purity in a quantitative yield.
  • the new bissteroidal ligands 3-5 have proven to be highly effective for the enantioselective reduction of ketones exemplified by the reduction of acetophenone and to be highly effective chiral lewis acids exemplified by the enantioselective cyclization of methyl-secone.
  • a dry 50 ml Schlenk tube containing a Teflon coated stirring bar was charged with solution of UAIH4 in THF (1. 5 ml, 0.98 M) and then a solution of ethyl alkohol in THF (0.9 ml, 1.7 M) was added dropwise for a period of ca. 10 min. Subsequently a THF solution of R-4 (3 ml, 0.53 M) was added dropwise for a period of 30 min. After stirring for additional 30 min. at room temperature the reducing agent was cooled to -90°C. A solution of acetophenone (0.45 ml, 0.7 M) in THF was added slowly (for a period of 20 min).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)

Abstract

Bissteroidal compounds of general formula (I), in which R1 stands for hydrogen, alkyl, acyl, fluorine, and X1R5, where X1 stands for oxygen and sulfur and R5 can either be hydrogen, alkyl, aryl; R2 stands for hydrogen and alkyl; the stereochemistry of C-13, C-14 and C-17 may either be a or b; X stands for oxygen, hydroxyl, trifluormethylsulfonyloxy, or (R6)2P, where R6 can be aryl, alkyl and cycloalkyl; R3 stands for hydrogen, alkyl, aryl, trialkylsilyl, fluorine and X2R6, where X2 stands for oxygen and sulfur and R6 stands for hydrogen, trifluormethylsulfonyl, alkyl, cycloalkyl or aryl. R4 can either be a substituent in the 6 or 7 position of the steroid with the meaning of hydrogen, alkyl, aryl, fluorine, and X3R7, where X3 stands for oxygen, sulfur or trialkylsilyl and R7 stands for hydrogen, trifluormethylsulfonyl, alkyl or aryl, and the B-ring of the steroid contains none or two double bonds. Enantio- and Diastereomeric derivatives of compounds of general formula (I), metal complexes thereof and their use in enantioselective reactions.

Description

Bissteroidat Compounds And Their Use For The Preparation Of Chiral Complexes
The invention relates to bissteroidal compounds and their use for the preparation of chiral complexes, useful as catalysts for various asymmetric syntheses.
Background of the invention
Chiral 2,2'-bis-Diphenylphosphino-1 ,1 'bi-2-naphtol (BINAP) introduced by Noyori (J. Am. Chem. Soc. 1980, 102, 7932) in 1980 has found wide application as a chiral ligand in asymmetric catalysis from laboratory up to industrial scale. The major drawbacks of the Noyori-BINAP synthesis are a bromination reaction at 240° to 320° C and a late resolution step of a BINAP precursor by crystallization with either camphorsulfonic acid or 2,3-O-dibenzoyltartaric acid as resolving agent, providing a overall low yield of the desired reagent (Nachr. Chem. Techn. Lab. 1996, 44, 996).
A new procedure by Verhoeven (US Patent 5,399,771) circumvents the tedious introduction of the diphenylphosphino group and provides a simpler preparation of BINAP via nickel catalyzed phosphinylation of the corresponding ditriflate of 1 ,1 '-Bi-2- naphtol (BINOL).
Nevertheless their improved synthesis of BINAP is still based on the resolution of BINOL with trans-1 ,2-Diaminocyclohexane as a resolving agent (J. Org. Chem. 1986, 51 , 629). Although steroids are potentially interesting compounds for asymmetric catalysis due to their rigid backbone the synthesis of 4,4'-bis(steroids) and any application thereof as chiral ligands in asymmetric catalysis is unprecedented so far. The present invention describes the diastereoselective synthesis of (Fta)- and (Sa)- 4,4'-bis(3-Diphenylphosphinoestra-1 ,3,5(10), 6, 8-pentaene) and the application of these new bisphosphines as chiral ligands in metal complexes for the enantioselective hydrogenation of β-ketoesters, α-β-unsaturated acids and dehydroaminoacids. Detailed description of the invention.
Bissteroidal compounds of general formula I
I in which
Rl stands for hydrogen, alkyl, acyl, fluorine, and X-1 R5, where X-| stands for oxygen and sulfur and R5 can either be hydrogen, alkyl, aryl,
R2 stands for hydrogen and alkyl; the stereochemistry of C-13, C-14 and C-17 may either be a or b,
X stands for oxygen, hydroxyl, trifluormethylsulfonyloxy, or (R6)2P, where Rg can be aryl, alkyl and cycloalkyl,
R3 stands for hydrogen, alkyl, aryl, trialkylsilyl, fluorine and X2R6. where X2 stands for oxygen and sulfur and
Rg stands for hydrogen, trifluormethylsulfonyl, alkyl, cyloalkyl or aryl. R4 can either be a substituent in the 6 or 7 position of the steroid with the meaning of hydrogen, alkyl, aryl, fluorine, and X3R7, where X3 stands for oxygen, sulfur or trialkylsilyl and R7 stands for hydrogen, trifluormethylsulfonyl, alkyl or aryl, and the B-ring of the steroid contains none or two double bonds.
Enantio- and Diastereomeric derivatives of compounds of general formula I. The alkyl radical of Ri - R7 have the meaning of lower alkyl substituents, for example the methyl-, ethyl-, propyl-, 2-methylethyl-, 2-methyl-propyl-, 3-methyl-propyl-, 2,2- dimethyl-ethyl- or butyl group. The acyl radical of Ri have the meaning of C1-C6- groups, per example acyl-, propionylic-, butyric or hexanoic group. The aryl group radical of R3, R4, R$, Rg and R7 have the meaning of phenyl-, benzyl- or 4-methyl- phenyl substituents. The cycloalkyl radical of Rg has the meaning of a cyclopentyl- or cyclohexyl group. The trialkylsilyl radical of R3 or X3 have the meaning of trimethyl- or tert.-butyldimethylsilyl.
3-Hydroxy-1 ,3,5(10)6,8-estrapentaen-17-one (Equilenin) 1 is submitted to the standard conditions of a Wolff- Kishner reduction (J. Am. Chem. Soc. 1946, 68, 2487) giving Estra-1 ,3,5(10),6,8-pentaen-3-ol 2 in 80-85% yield.
1
The targets (Ra)- and (Sa)-4,4'-bis(Estra-1 , 3,5(10),6,8-pentaen-3-ol) (bisequilenol) 3 are prepared from Estra-1 , 3,5(10) ,6, 8-pentaen-3-ol 2 via metal catalyzed phenolic coupling. The coupling is performed with catalytic amounts of a copper-amine complex in methylenechloride under an oxygen atmosphere (Tetrahedron Lett. 1994, 35, 7983). generating the diastereomers S-3 and R-3. In contrast to the Noyori BINOL synthesis these two diastereomers can be easily separated by flash chromatography thus avoiding the lengthy resolution of enantiomers with an additional resolution agent. The absolute configuration of the new ligands (Ra)- and (Sa)-4,4'-bis(Estra-
1 , 3,5(10),6,8-pentaen-3-ol) 3, (Ra)- and (Sa)-4,4'-bis(Estra-1 , 3,5(10)-trien-3-ol) 5 and (Ra)- and (Sa)-4,4'-bis(3-diphenylphosphinoestra-1 ,3,5(10),6I8-pentaene) 7 were determined by CD spectroscopy in comparison to the CD spectra of the ligand (Ra)- bis(17-beta-Methoxyestra-1 ,3,5(10)-trien-3-ol) R-4 whose absolute configuration was determined by X-ray crystallography.
Furthermore the diastereoselectivity of the coupling shows a temperature dependance favouring the R-isomer at room temperature with a diasteromeric excess of 50%. At lower temperature the selectivity is inverted, favouring the S-isomer with almost the same diasteromeric excess (Table 1). In order to make both isomers available the coupling is performed at 0° C providing both diastereomers in a combined yield of 92-96%.
S-3 R-3
Table 1. Dependence of the diasteroselectivity of the copper mediated coupling on the
The intriguing feature of these new compounds R-3 and S-3 is that they behave as true enantiomers in any type of asymmetric reactions despite of their diastereomeric nature.
This was first shown testing the set of bissteroids 3-5 in enantioselective reductions of acetophenone following the Noyori protocol (J. Am. Chem. Soc. 1979, 101 , 3129); (Table 2).
Table 2. Enantioselective reductions of acetophenone induced b bissteroid li ands
a) determined by GC
The results in table 2 show that the new bissteroids are as powerful as reducing agents as Noyori's BINOL. The lower enantiomeric excess for the ligands 3 and 5 are due to solubility problems at very low temperatures which prevent the reduction to be carried out at -90° C as in the Noyori protocol. With ligand 4, which is completely soluble at -90° C the same enantiomeric excess in the reduction of acetophenone is achieved as Noyori.
The absolute configuration of the reduction products is also the same as in the Noyori reduction. As expected the reduction with the two diasteromeric ligands R-3 and S-3 produce the opposite enantiomers of the reduction product.
The bissteroids R-/S-4 and R-/S-5 were prepared by copper mediated coupling
(Tetrahedron 1992, 48, 2579) of the lithiated 4-Bromo-17β-methoxy-3- methoxymethoxyestra-1 , 3,5(10)-triene (Tetrahedron 1991 , 47, 2871) 11 and 4-Bromo-
3-methoxymethoxyestra-1 , 3,5(10)-triene 14.
Furthermore the diasteromeric ligands R-3 and S-3 were incorporated into the chiral titanium catalysts R-Ti-1 and S-Ti-1 (Tetrahedron Lett. 1991 , 32, 6571). These catalysts were then applied as chiral lewis acids for the enantioselective cyclization of
Methylsecone, yielding 3-Methoxyestra-1 ,3,5(10),8,14-pentaene-17-one in remarkably high yield and enantiomeric excess (Table 3).
R-Ti-l X=BF4 S-Ti-1 X=BFΛ
Most interestingly, the catalysts R-Ti-1 and S-Ti-1 afford the product 3-Methoxyestra- 1 , 3,5(10),8,14-pentaene-17-one due to their diastereomeric nature with a different chemical and optical yield each.
The synthesis of (Ra)- and (Sa)-4,4'-bis(3-Trifluoromethylsulfonyloxyestra- 1 ,3,5(10),6,8-pentaene) 6 was accomplished by triflation of R-/S-3 with triflic acid anhydride in the presence of pyridine in quantitative yield.
R-/S-3 R-/S-6
The triflate 6 was then converted into the bisphoshine 7 without any isomerisation of the diastereomers in 83% yield.
R-/S-6 R-/S-7
Starting with Equilinin 1 both bisphosphines R-7 and S-7 are available in 4 chemical steps in an overall yield of 64%.
The epimeric phosphines Epi-R-7 and Epi-S-7 are available according to a similar synthetic sequence starting with 14-Epi-equilenine 14-Epi-1 (Tetrahedron Lett. 1971 ,
4179).
14-epi-1 14-epi-R-/S-6
14-eρi-R-/S-6 14-epi-R-/S-7
The new phosphines R-7 and S-7 were tested as chiral ligands in a ruthenium complex for the asymmetric hydrogenation of methyl-acetoacetate, N-acetyl-cinnamic acid and tiglic acid as representative examples (Table 3).
The chiral ruthenium complex is prepared by heating the bisphosphines R-/S-7 with [RuCI2(benzene)]2 in DMF (Tetrahedron Lett. 1991 , 32, 4163).
Table 3. Asymmetric hydrogenation of Methyl-acetoacetate and N-Acetyl-cinnamic acid
*1 h/ 100 atm/ 100°C; **48h/ 7atm; ***24 h/ 4atm; ****96h /7 atm;
The new chiral complexes synthesized from [RuCI2(benzene)]2 and the bissteroidal ligands 7 are more powerful than the state-of-the-art BINAP-ruthenium complexes of Noyori as they are of broader applicability and allow the preparation of a range of substrates of extraordinary high enantiomeric purity in a quantitative yield. In addition the new bissteroidal ligands 3-5 have proven to be highly effective for the enantioselective reduction of ketones exemplified by the reduction of acetophenone and to be highly effective chiral lewis acids exemplified by the enantioselective cyclization of methyl-secone.
Preparative Examples
Optical rotations were measured on a Perkin Elmer 241 Polarimeter, melting points are not corrected; 1 H-NMR (300 MHz), and 13C-NMR (75 MHz) spectra were taken on General Electric QE 300 in CDCI3 as a solvent and internal reference (7.28 ppm, 81.9 ppm); J values are given in Hz; IR spectra were taken on Nicolet 20 SBX; Mass spectra were recorded on TRIO2; TLC were performed on Merck 60 F 254. Silica gel 60G (240-400 mesh) was used for column chromatography. All reactions were carried out under dry nitrogen or argon.
1. Synthesis of the phosphines R-/S-7:
1. A suspension of 53,15 g 3-Hydroxy-1 ,3,5(10)6,8-estrapentaen-17-one 1 (0,199 mmoles) in 36,3 ml hydrazine hydrate, 435 ml diethyleneglycol and 36,5 g NaOH (0,91 mole) is heated on an oil bath to 120° C. After stirring at this temperature for 0,5 hour the temperature is increased to 180°-190° C and stirred for additional 8 hrs. After cooling to room temperature the solution is added to 500 ml of ice cooled water and then acidified with cone. HCI to pH 0. The precipitate is filtered off, dried and the crude product is recrystallized from water-ethanol 1 :1 (100 ml each) giving 42,7 g Estra- 1 ,3,5(10),6,8-pentaen-3-ol 2 (85%); mp = 136,5°-139°C; [a] 365 = + 228.7° (c=10.2 in THF).
2. To a solution of Estra-1 , 3,5(10), 6,8-pentaen-3-ol 2 (10g, 20mmol ) in CH2CI2 (300 ml) was added CuCI(OH)TMEDA (0.800 g,0.35 mmol) and the solution was stirred at 0°C for 10-15 min while bubbling oxygen through the mixture. The reaction was monitored by TLC. At the end of the reaction HCI (10%, 5 ml) was added to the mixture and stirred for additional 15 min (the colour was changed from blue to yellow). The mixture was filtered and the residue was dried under vacuum to give crude product (5 g). From the filtrate after extraction with CH CI2 (3 X 10 ml) was isolated additionally 4.8 g product which was combined with the first fraction. The crude mixture was separated to give 5.9 g (Ra)-4,4'-bis(estra-1 ,3,5(10),6,8-pentaen-3-ol) 3 (59%) as main isomer; m.p. 207,4-207,5°C; [a] 365 = + 303.13° (c=1.6 in THF); 1 H-NMR: 8.15 (1 H, d, J=10.0 Hz), 7.38 (1 H, d, J=10.0 Hz), 7.09 (1 H, d, J=7.5 Hz), 7.01 (1 H, d, J=7.5 Hz), 4.98 (1 H, s, OH), 0.70 (3H, s); 13C-NMR: 151.3 (s), 135.2 (s), 131.8 (s), 130.9 (s), 127.6 (s), 126.5 (d), 126.1 (d), 122.0 (d), 116.8 (d), 111.7 (s), 49.7 (d), 40.4 (s), 38.7 (t), 35.8 (t), 25.2 (t), 24.7 (t), 20.9 (t), 16.2 (q); MS-CI: 520 (100, M+ + 1 + NH3) , 503 (90, M+); MS-EI: 502 (100, M+), 389 (5), 235 (10), 195 (5), 157 (7); and 3.7 g (Sa)-4,4'-bis(Estra-1 , 3,5(10),6,8-pentaen-3-ol) 3 as minor isomer (37%), m.p. 287,0°C decomp. (Hexane) ; [a] 365 = + 145.18° (c=1.4 in THF); 1 H-NMR: 8.10 (1 H, d, J=9.0 Hz), 7.32 (1 H, d, J=9.0 Hz), 7.05 (1 H, d, J=6.0 Hz), 6.98 (1 H, d, J=6.0 Hz), 5.10 (1 H, s, OH), 0.70 (3H, s); 1 3C-NMR: 151.3 (s), 135.1 (s), 131.6 (s), 130.9 (s), 127.6 (s), 126.5 (d), 126.1 (d), 121.8 (d), 116.8 (d), 111.7 (s), 49.7 (d), 40.4 (s), 38.7 (t), 35.8 (t), 25.2 (t), 24.7 (t), 20.9 (t), 16.2 (q); MS-CI: 520 (88, M+ + 1 + NH3), 503 (100, M+); MS-EI: 502 (100, M+), 389 (5), 251 (6), 235 (10), 195 (5), 157 (7);
3. To a solution of (Sa)-4,4'-bis(Estra-1 , 3,5(10), 6, 8-pentaen-3-ol) 3 (1.8 g, 3.6 mmol ) in toluene-pyridine 15:1 (30 ml) was added over period of 30 min dropwise triflic anhydride and mixture was stirred for additional 30 min. The solution was diluted with water, the organic layer was washed with brine, dried with Na2SO4 and the solvent was evaporated. The residue was filtered through SiO2 to yield crude product (2.8 g) which after crystallisation from hexane gave 2,5 g pure triflate (Sa)-4,4'-bis(3- Trifluoromethylsulfonyloxyestra-1 , 3,5(10),6,8-pentaene) 6 (90%), m.p.=+168.2°C; [a] D= - 97.6° (c= 1.7 in THF), 1 H-NMR: 8. 25 (1 H, d, J=10.0 Hz), 7.58 (1 H, d, J=10.0 Hz), 7.12 (1 H, d, J=9.0 Hz), 7.01 (1 H, d, J=9.0 Hz), 0.65 (3H, s); 13C-NMR: 144.3 (s), 138.5 (s), 131.6 (s), 130.9 (s), 130.7 (s), 126.9 (d), 126.6 (d), 124.3 (d), 123.5 (s), 118.2 (d), 49.9 (d), 40.3 (s), 38.6 (t), 35.6 (t), 24.9 (t), 24.7 (t), 20.8 (t), 16.2 (q); 19F- NMR: 87.12; MS-CI: 784 (3, M+ + 1 + NH3), MS-EI: 766 (100, M+), 633 (7) 483 (85), 389 (6), 309 (7),
(Ra)-4,4'-bis(3-Trifluoromethylsulfonyloxyestra-1 ,3,5(10),6,8-pentaene) 6:
The compound was synthezised according to the same procedure as (Sa)-4,4'-bis(3- Trifluoromethylsulfonyloxyestra-1 ,3,5(10), 6, 8-pentaene) 6 to give after recrystallisation pure compound; m.p.=201.9°C. [a] D= - 88.2° (c= 1.0 in THF), 1 H-NMR: 8. 25 (1 H, d, J=10.0 Hz), 7.59 (1 H, d, J=10.0 Hz), 7.12 (1 H, d, J=9.0 Hz), 7.01 (1 H, d, J=9.0 Hz), 0.66 (3H, s); 13C-NMR: 144.3 (s), 138.5 (s), 131.6 (s), 131.0 (s), 130.7 (s), 126.9 (d), 126.8 (d), 124.3 (d), 123.5 (s), 1 18.2 (d), 49.9 (d), 40.3 (s), 38.6 (t), 35.6 (t), 24.9 (t), 24.7 (t), 20.8 (t), 16.2 (q); 1 9F-NMR: 87.12; MS-CI: 784 (8, M+ + 1+ NH3), MS-EI: 766 (100, M+), 633 (7) 483 (75), 389 (6), 309 (7),
4. To solution of NiCI2dppe (0.070 g, 0.13 mmol) in dimethyl acetamide (2 ml) was added diphenylphosphine (0.13 ml, 0.75 mmol) at room temperature, and the solution was heated to 100°C. After 45 min, a solution of triflate (Ra)- or (Sa)-4,4'-bis(3- Trifluoromethylsulfonyloxyestra-1 ,3,5(10), 6, 8-pentaene) (1 g,1.3mmol) and 1 ,4- diazabicyclo[2.2.2]octane (0.62 g, 5.5 mmol) in dimethyl acetamide (4 ml) was added at once, the resulting green solution was kept at 100°C and three additional portions of diphenylphosphine (3 X 0.13 ml) were added at 1 , 3 and 5 h later. The reaction was kept at 100°C for six days and then the dark brown solution was diluted with MeOH. The desired product was filtered and the filter cake was washed with MeOH and dried under vacuum. The crude product (0.820 g, 80%) was recrystallised from MeOH/Tol 10:1 to give 0.78 g pure phosphine
(Ra)-4,4'-bis(3-Diphenylphosphinoestra-1 , 3,5(10),6,8-pentaene) 7: (70%), 1 H-NMR: 8. 05 (1 H, d, J=10.0 Hz), 7.42 (1 H, brd, J=10.0 Hz), 7.3-6.9 (10H, m) 6.50 (2H, ABq, J=8.0 Hz), 3.30 (2H, brd, J=8.5Hz), 2.63 (1H, dd, J= 5.1 , 11.0 Hz), 2.2-1.3 (7H, m), 0.70 (3H, s); 13C-NMR: 145.8 (s), 138.8 (s), 137.4 (s), 133.6 (s), 132.6 (s), 131.6 (s), 130.6 (s), 130.1 128.3, 128.2, 127.6, 125.7, 124.9, 123.3, 50.3 (d), (each d), 40.7 (s), 39.0 (t), 36.1 (t), 25.4 (t), 24.9 (t), 21.2 (t), 16.8 (q); 31 P-NMR: -15.42 (s); MS-CI: 784 (8, M+ + 1 + NH3), MS-EI: 766 (100, M+), 633 (7) 483 (75), 389 (6), 309 (7), (Sa)-4,4'-bis(3-Diphenylphosphinoestra-1 ,3,5(10),6,8-pentaene) 7: (70%), [a] p = - 97.6° (c = 0.17 in THF), 1 H-NMR: 7. 92 (1 H, d, J=10.0 Hz), 7.39 (1 H, brd, J=10.0 Hz), 7.3-6.9 (10H, m), 6.75 (2H, ABq, J=8.0 Hz), 3.38 (1 H, dd, 5.6, 21.0 Hz), 3.22 (1 H, m), 2.72 (1 H, dd, 6.5,11.6 Hz), 2.12 (2H, m), 1.9-1.3 (5H, m), 0.55 (3H, s); 1 3C-NMR: 146.2 (s), 137.6 (s), 133.5 (s), 133.1 (s), 132.5 (s), 131.8 (s) 131.5 (s), 130.0 (d), 129.9 (s), 127.6 ,127.5, 126.9, 125.5, 124.8, 122.9 50.0 (each d), 40.3 (s), 38.7 (t), 35.8 (t), 25.0 (t), 24.6 (t), 20.8 (t), 16.4 (q); 31p-NMR: -14. 42 (s); MS-CI: 784 (8, M+ + 1 + NH3), MS-EI: 766 (100, M+), 633 (7) 483 (75), 389 (6), 309 (7).
2. Synthesis of the phosphines Epi-R-/S-7:
1. To a suspension of 14-Epi-3-hydroxy-1 ,3,5(10)6,8-estrapentaen-17-one 14- Epi-1 (10g, 38mmol ) in CH2CI2 (300 ml) was added CuCI(OH)TMEDA (0.800 g,0.35 mmol) and the solution was stirred at 0°C for 10-15 min while bubbling oxygen through the mixture. The reaction was monitored by TLC. At the end of the reaction HCI (10%, 5 ml) was added to the mixture and stirred for additional 15 min (the colour was changed from blue to yellow). The organic layer was washed with brine, dried and the solvent was evaporated. The crude mixture (9.9 g) was separated to give 5.2 g (Ra)- 4,4'-bis(14-Epi-3-hydroxy-1 ,3,5(10)6,8-estrapentaen-17-one) (52%); m.p. 293°C decomp.; [a] 365 = + 139.5° (c=2.4 in THF);
1 H-NMR: 8.17 (1 H, d, J=9.3 Hz), 7.38 (1 H, d, J=9.3 Hz), 7.07 (1 H, d, J=8.5 Hz), 6.98 (1 H, d, J=8.5 Hz), 4.85 (1 H, s, OH), 1.50 (3H, s); MS-CI: 520 (100, M+ + 1 + NH3), 503 (90, M+) ; MS-EI: 530 (100, M+), 474 (15), 209 (20), 181 (25), 165 (20);
and 4.3 g (Sa)-4,4'-bis(14-Epi-3-hydroxy-1 , 3,5(10)6, 8-estrapentaen-17-one) (43%), m.p. 180°C decomp. (Hexane) ; [a] 365 = + 154.0° (c=2.0 in THF); 1 H-NMR: 8.15 (1 H, d, J=9.3 Hz), 7.42 (1 H, d, J=9.3 Hz), 7.15 (1 H, d, J=8.6 Hz), 7.05 (1 H, d, J=8.6 Hz), 4.98 (1 H, s, OH), 1.19 (3H, s); MS-CI: 520 (88, M+ + 1 + NH3), 503 (100, M+); MS-EI: 530 (100, M+), 474 (15), 209 (36), 181 (38), 165 (40);
2. To a solution of (Sa)-4,4'-bis(14-Epi-3-hydroxy-1 ,3,5(10)6,8-estrapentaen-17- one) (2.2 g, 4.2 mmol ) and N-ethyldiisopropylamine (4ml, 23 mmol) in Toluene (60 ml) was added over period of 30 min dropwise triflic anhydride (3.6 ml, 10 mmol). The mixture was stirred for 30 min. at room temperature and then heated to 60°C and kept at this temperature for 3 hours. At the end of the reaction the mixture was cooled down and the upper (toluene) layer was separated and washed with water, 2N HCI and brine, dried with Na SU4 and the solvent was evaporated. The residue was dissolved in ethanol (30 ml) and exposed to hydrogen (1 atm) in the presence of PtO2 (0.2 g) for 2h. The mixture was filtered through a pad of celite, the solvent was evaporated and the crude product was dissolved in ethyl acetate. The solution was washed with NaHCθ3, brine and dried with Na2Sθ4. The solvent was evaporated and the crude product was separated on a Siθ2 to yield (Sa)-4,4'-bis (14-Epi-3- trifluoromethylsulfonyloxyestra-1 ,3,5(10),6,8-pentaene) 14-Epi-S-6 (2.6 g) (86%), mp=115-116°C; [a] D= + 128.8° (c= 0.1 in THF), 1 H-NMR: 8. 28 (1 H, d, J=10.0 Hz), 7.60 (1 H, d, J=10.0 Hz), 7.12 (1 H, d, J=9.0 Hz), 6.98 (1 H, d, J=9.0 Hz), 1.10 (3H, s); 1 3C-NMR: 144.8 (s), 139.2 (s), 132.0 (s), 131.4 (s), 130.7 (d), 130.4 (s), 126.6 (d), 124.5 (d), 120.3 (s), 1 18.5 (d), 50.7 (d), 40.7 (t), 39.3 (s), 35.4 (t), 31.4 (t), 25.7 (q), 23.2 (t), 22.7 (t); MS-CI: 784 (100, M+ + 1 + NH3), MS-EI: 766 (80, M+), 633 (17) 483 (100), 387 (21), 308 (17),
(Ra)-4,4'-bis(14-Epi-3-trifluoromethylsulfonyloxyestra-1 , 3,5(10), 6, 8-pentaene) 14-Epi- R-6:
The compound was synthesised according to the same procedure as (Sa)-4,4'-bis (14- Epi-3-trifluoromethylsulfonyloxyestra-1 ,3,5(10),6,8-pentaene) 14-Epi-S-6 to give after recrystallisation pure compound; m.p.=204-204.5°C, [a] Q= - 23.9° (c=0.1 in THF), 1 H- NMR: 8. 28 (1 H, d, J=10.0 Hz), 7.60 (1 H, d, J=10.0 Hz), 7.11 (1 H, d, J=9.0 Hz), 7.01 (1 H, d, J=9.0 Hz), 1.10 (3H, s); 1 3C-NMR: 144.3 (s), 139.2 (s), 132.0 (s), 131.4 (s), 130.8 (d), 130.5 (s), 127.0 (d), 124.6 (d), 124.9 (s), 118.5 (d), 50.6 (d), 40.6 (t), 39.6 (s) 35.4 (t), 31.5 (t), 25.7 (q), 23.3 (t), 22.8 (t), MS-CI: 784 (88, M+ + 1 + NH3), MS-EI: 766 (100, M+), 633 (17) 483 (75), 389 (26), 309 (7),
3. To solution of NiC^dppe (0.070 g, 0.13 mmol) in dimethyl acetamide (2 ml) was added diphenylphosphine (0.13 ml, 0.75 mmol) at room temperature, and the solution was heated to 100°C. After 45 min, a solution of triflate (Ra)- or (Sa)-4,4'-bis (14-Epi-3- trifluoromethylsulfonyloxyestra-1 ,3,5(10),6,8-pentaene) (1g,1.3mmol) and 1 ,4- diazabicyclo[2.2.2]octane (0.62 g, 5.5 mmol) in dimethyl acetamide (4 ml) was added at once, the resulting green solution was kept at 100°C and three additional portions of diphenylphosphine (3 X 0.13 ml) were added at 1 , 3 and 5 h later. The reaction was kept at 100°C for six days and then the dark brown solution was diluted with MeOH. The desired product was filtered and the filter cake was washed with MeOH and dried under vacuum. The crude product (0.820 g, 80%) was recrystallised from MeOH/Tol 10:1 to give 0.78 g pure phosphine.
(Sa)-4,4'-bis(14-Epi-3-diphenylphosphinoestra-1 ,3,5(10),6,8-pentaene) 14-Epi-7: (89%),
[a] D = - 79.3° (c = 0.13 in THF), 1 H-NMR: 7. 98 (1 H, d, J=10.0 Hz), 7.36 (1 H, brd, J=10.0 Hz), 7.3-6.9 (10H, m), 6.52 (2H, s), 3.12 (1 H, dt, 3.2, 21.0 Hz), 2.95 (1 H, m), 2.52 (1 H, t, 7.5 Hz), 2.1 (2H, m), 1.7 (1 H, m), 1.9-1.3 (5H, m), 0.98 (3H, s); 1 3C-NMR: 146.4 (s), 146.0 (s), 138.2 (s), 133.1 (s), 132.8 (s), 132.0 (s) 129.5 (s), 129.9 (s), 130.3 128.8, 128.3, 127.9, 127.4, 125.6, 123.2 50.0 (each d), 40.3 (s), 38.7 (t), 35.8 (t), 25.0 (t), 24.6 (t), 20.8 (t), 16.4 (q); 31P-NMR: -15.2 (s);
3. Synthesis of (Ra)-bis(17 beta-Methoxyestra-1 ,3,5(10)-trien-3-ol) 4 and (Ra)-4,4- bis(Estra-1 ,3,5(10)-trien-3-ol) 5
R , = H : 8
L7 R = OH : 10
K1 = MOM : R = OMe : 11
X = OMe, S-12 X » OMe, .H: R-12
X H,H: l S- -15 X H,H| -15
X = OMe,H: R-12 X = OMe,H: R- X = H,H: R-15 X = H,H: R-5
3.1 Synthesis of (Ra)-bis(17 beta-Methoxyestra-1, 3,5(10)-trien-3-ol) 4:
1. To solution of 4-Bromo-3-hydroxyestra-1 ,3,5(10)-trien-17-one 8 (20g, 51 mmol) in dimethyl formamide (250 ml) was added t-BuOK (7.7g, 74 mmol) at 0°C. The mixture was stirred for 5 min and then a solution of methoxymethyl chloride (5.5 g, 68 mmol) in dimethyl formamide (15 ml) was added dropwise at the same temperature and stirred for additional 1 h. The reaction was quenched with saturated NH4CI and diluted with water (130 ml). The crude product was filtered and recrystallized from ethanol to give 21.5 g pure 4-Bromo-3-methoxymethoxyestra-1,3,5(10)-trien-17-one 9 (95.5%); m.p.172° ;
2. 4-Bromo-3-methoxymethoxyestra-1, 3,5(10)-trien-17-one 9 (20 g) was reduced with 10,6 g NaBH4 (15 mmoles) in 300 ml methanol to give the alcohol 4-Bromo-3- methoxymethoxyestra-1 ,3,5(10)-trien-17-beta-ol 10 (20g) which was used without purification for the next step. 3. To solution of 4-Bromo-3-methoxymethoxyestra-1 ,3,5(10)-trien-17 beta-ol 10 (20g, 50 mmol) in DMF (250 ml) was added t-BuOK (7.9 g, 75 mmol) at 0°C. The mixture was stirred for 5 min and then a solution MeJ (9.2 g, 65 mmol) in dimethyl formamide (15 ml) was added dropwise at the same temperature and stirred for additional 15 h. The reaction was quenched with saturated NH4CI and diluted with water (130 ml). The crude product was filtered and recrystallized from ethanol to yield 19.7 g 4-Bromo-17 beta-methoxy-3-methoxymethoxyestra-1 ,3,5(10)-trien 11 (94%); 365 = + 49-6° (c=1 in THF): 1 H-NMR: 7.18 (1 H, d, J=9.0 Hz), 6.95 (1 H, d, J=9.0 Hz), 5.22 (2H, s), 3.52 (3H, s), 3.48 (3H, s), 3.30 (1 H, t, J=7.5 Hz), 2.98 (1 H, dd, J=5.8, 19.5 Hz), 2.70 (1 H, m), 0.75 (3H, s); 3C-NMR: 151.3 (s), 137.3 (s), 135.8 (s), 124.4 (d), 115.9 (s), 113.0 (d), 94.9 (t), 90.4 (d), 57.4 (d), 55.9 (s), 49.9 (d), 43.8 (d), 42.8 (s), 37.6 (t), 37.4 (d), 30.8 (t), 27.4 (t), 27.1 (t), 26.3 (t), 22.7 (t), 1 1.1 (q); Anal. Calcd. (C2ι H23Br) C-61.75, H-7.16, O- 1 1.76, Br-19.52; Found: C-60.95, H-7.80, O-1 1.72, Br-19.60.
4. To solution of 4-Bromo-17-beta-methoxy-3-methoxymethoxyestra-1 ,3,5(10)- trien 11 (10 g, 24.4 mmol) in THF (250 ml) was added BuLi (16 ml, 1.6 M, 26 mmol) at -60°C. The mixture was stirred for 30 min and then a suspension of CuCN (1.1 g, 12 mmol) in THF (25 ml) was added at the same temperature. The stirring was continued for additional 2.5 h until no CuCN was visible at the bottom of the flask. After cooling to -100°C dry oxygen was passed through the mixture for 15 min. which resulted in a deep purple colour. The oxygen flow was disconnected and the reaction mixture was stirred for additional 30 min at this temperature and then quenched with saturated NH4CI and diluted with diethyl ether (100 ml). The organic layer was washed with brine, dried with Na2SO4 and the solvent was evaporated. The crude mixture (7.8 g) was crystallized from ethyl acetate-hexanes 8:1. The solid product was filtered and dried to give 2.9 g of pure isomer (Ra)-4,4'-bis(17-beta-Methoxy-3- methoxymethoxyestra-1 ,3,5(10)-triene) 12 (36%). The filtrate was evaporated and the residue was separated by chromatography on Siθ2 (hexane:diethyl ether-6:1) to give additional product (0.2 g, 2%) which was combined with a first one and used without further purification.
1 H-NMR (crude): 7.28 (1 H, d, J=9.0 Hz), 7.05 (1 H, d, J=9.0 Hz) , 5.09 (1 H, d, J=6.0 Hz), 4.95 (1 H, d, J=6.0 Hz), 3.48 (3H, s,), 3.30 (1 H, t, J=8.5 Hz), 3.30 (3H, s), 0.80 (3H, s); 1 3C-NMR: 151.7 (s), 136.1 (s), 134.1 (s), 126.3 (s), 124.6 (d), 111.9 (d), 94.2 (t), 81.5 (d), 55.2 (d), 52.9 (s), 50.0 (d), 44.0 (d), 42.9 (t), 37.9 (d), 36.5 (t), 30.3 (t), 26.9 (t), 25.9 (t), 22.7 (t), 16.2 (q); 5. To solution of (Ra)-4,4'-bis(17-beta-Methoxy-3-methoxymethoxyestra-1 ,3,5(10)- triene) 12 (2g, 3 mmol) in Methanol/THF/^O 1 :1 :0.2 (20 ml) was added concentrated HCI (3ml) the mixture was stirred for 25 h at rt. The reaction mixture was neutralized with saturated NaHCO3 and diluted with ethyl ether (50 ml). The organic layer was washed with brine, dried with Na2SO4 and the solvent was evaporated. The crude product (1.3 g, 78%) was recrystalised from Hexane ethyl ether 1 :1 to give 1.1 g (Ra)- bis(17-beta-Methoxyestra-1 , 3,5(10)-trien-3-ol) 4 (70%); m.p. 181 °C, [a] 365 = - 96.30° (c=1.54 in THF); 1 H-NMR: 7.25 (1 H, d, J=10.0 Hz), 6.82 (1 H, d, J=10.0 Hz), 4.72 (1 H, s, OH), 3.38 (3H, s), 3.32 (1 H, t, J=7.5 Hz), , 0.80 (3H, s); 13C-NMR: 150.7 (s), 136.6 (s), 133.3 (s), 126.8 (d), 124.6 (s), 112.9 (d), 90.4 (d), 57.5 (d), 50.0 (s), 43.8 (d), 42.8 (t), 37.8 (d), 37.6 (t), 27.3 (t), 26.9 (t), 26.7 (t), 22.6 (t), 11.2 (q); Anal. Calcd. (C38H50°4) C-79.96, H-8.83, Found: C-79.46, H-7.90.
3.2 Synthesis of (Ra)-4,4'-bis(Estra-1 , 3,5(10)-trien-3-ol) 5:
1. To solution of 4-Bromo-3-hydroxy-estra-1 ,3,5(10)-triene (20g, 60 mmol) in dimethyl formamide (250 ml) was added t-BuOK (9.3g, 89 mmol) at 0°C. The mixture was stirred for 5 min and then a solution methoxymethyl chloride (6.3 g, 78 mmol) in DMF (15 ml) was added dropwise at the same temperature and stirred for additional 1 h. The reaction was quenched with saturated NH4CI and diluted with water (130 ml). The crude product was filtered and recrystallized from ethanol to give 20.4 g 4-Bromo- 3-methoxymethoxy-estra-1 ,3,5(10)-triene 14 (90%); m.p. 85.2°C, [a ]rj = + 50,8° (c=1 in THF); 1 H-NMR: 7.22 (1 H, d, J=9.0 Hz), 6.97 (1 H, d, J=9.0 Hz), 5.22 (2H, s,), 3.55 (3H, s,), 0.72 (3H, s); 1 3C-NMR: 151.3 (s), 135.2 (s), 131.8 (s), 130.9 (s), 127.6 (s), 126.5 (d), 94.2 (t), 81.5 (d), 55.2 (d), 52.9 (s), 50.0 (d), 44.0 (d), 42.9 (t), 37.9 (d), 36.5 (t), 30.3 (t), 26.9 (t), 25.9 (t), 22.7 (t), 16.2 (q); MS-CI: 398, 396 (100, M+ + 1 + NH3); MS-EI: 380, 378 (30, M+), 350, 348 (25), 251 (6), 173 (10); Anal. Calcd. (C20H22Br) C-63.33, H-7.17, O-8.44, Br-21.06; Found: C-63.28, H-7.20, Br-21.00;
2. To solution of 4-Bromo-3-methoxymethoxy-estra-1 ,3,5(10)-triene 14 (12 g, 31.7 mmol) in THF (250 ml) was added BuLi (24 ml, 1.6 M, 38 mmol) at -60°C. The mixture was stirred for 30 min and then a suspension of CuCN (1.5 g, 17mmol) in THF (25 ml) was added at the same temperature. The mixture was stirred for additional 2.5 h until no CuCN was visible at the bottom of the flask. After cooling to -100° dry oxygen was passed through the mixture for 15 min. The oxygen flow was disconnected and the reaction mixture was stirred for additional 30 min at this temperature and then quenched with saturated NH4CI and diluted with diethyl ether (100 ml). The organic layer was washed with brine, dried with Na2SU4 and the solvent was evaporated. The residue (10 g) was dissolved in DMF (30 ml) and to the solution was added t-BuOK (1.9 g, 18 mmol) at 0°C. The mixture was stirred for 5 min and then a solution of TBDMSCI (2.5 g, 65 mmol) in DMF (15 ml) was added at the same temperature and stirred for additional 30 min. The reaction was quenched with saturated NH4CI and diluted with ethyl ether (50 ml). The organic layer was washed with brine, dried with Na2SO4 and the solvent was evaporated. The crude mixture (11 g) was separated by chromatography on Siθ2 (hexane:diethyl ether-6:1) to give 2 g of crystalline product (Ra)-4,4'-bis(3-Methoxymethoxyestra-1 , 3,5(10)-triene) 15 (21 %) which was used without purification for the next step.
3. To solution of (Ra)-4,4'-bis(3-Methoxymethoxyestra-1 ,3,5(10)-triene) 15 (2g, 3.3 mmol) in Methanol/THF/^O 1 :1 :0.2 (20 ml) was added cone. HCL (3ml) and stirred for 25 h at room temperature. The reaction mixture was neutralized with saturated aHCθ3 and diluted with ethyl ether (50 ml). The organic layer was washed with brine, dried with Na2SU4 and the solvent was evaporated. The crude product (1.3 g, 78%) was recrystallised from hexane / ethyl ether 1 :1 to give 1 ,3 g (Ra)-4,4'-bis(Estra- 1 , 3,5(10)-trien-3-ol) 5 (76%), m.p.162.5°C, [a] 365 = - 96.30° (c=1.54 in THF); 1 H- NMR: 7.25 (1 H, d, J=10.0 Hz), 6.82 (1 H, d, J=10.0 Hz), 4.72 (1 H, brs, OH), 0.72 (3H, s); 13C-NMR: 150.8 (s), 136.7 (s), 133.6 (s), 126.8 (d), 111.8 (s), 112.3 (d), 53.3 (d), 43.9 (d), 40.7 (s), 40.2 (t), 38.5 (t), 38.3 (d), 27.6 (t), 27.1 (t), 26.4 (t), 24.8 (t), 20.2 (t), 14.8 (q); MS-CI: 520 (100, M+ + 1 + NH3), 503 (92, M+ + 1); MS-EI: 520 (100, M+), 251 (4), 235 (6); Anal. Calcd. (C36H46O2) C-84.66, H-9.08, Found: C-84.94 H-9.12, O-6.20.
Examples of applications:
1. Reduction of acetophenone with ligand R-4:
A dry 50 ml Schlenk tube containing a Teflon coated stirring bar was charged with solution of UAIH4 in THF (1. 5 ml, 0.98 M) and then a solution of ethyl alkohol in THF (0.9 ml, 1.7 M) was added dropwise for a period of ca. 10 min. Subsequently a THF solution of R-4 (3 ml, 0.53 M) was added dropwise for a period of 30 min. After stirring for additional 30 min. at room temperature the reducing agent was cooled to -90°C. A solution of acetophenone (0.45 ml, 0.7 M) in THF was added slowly (for a period of 20 min). The mixture was stirred for additional 3 h at this temperature and at -78°C for 16 h. After addition of methanol (0.5 ml) at -78°C the mixture was warmed up to room temperature, neutralized to pH=6 with HCL (5%) and extracted with ethyl ether (2 X10 ml). GC analysis (25 m FS-Hydrodex-B-PM, 110 isoterm, 1 bar Hydrogen, t° detector=280°C, t° column = 280°C) of the extract shows 96.5% ee and complete conversion.
2. Hydrogenation of olefins and b-Ketoesters and with ligand R-4:
A dry 50 ml Schlenk tube containing a Teflon coated stirring bar was charged with [RuCI2(benzene)] (0.018 g, 0.036 mmol), S-4 (0.07 g, 0.073 mmol) and DMF (1 ml). The resulting brown suspension was heated at 100°C under argon for 30 min to give a clear reddish brown solution. The reaction mixture was cooled and concentrated at 1 mm Hg and then at 0.05 mm Hg for 1 h to give RuCI2(S-4)(DMF)2.
a) Hydrogenation of methyl acetoacetate
To the resulting reddish brown solid of RuCl2(S-4)(DMF)2 was added a solution of methyl acetoacetate (7.3 g, 63 mmol) in degassed methanol (40 ml) and stirred for 5 min. Then the solution was transferred to 125 ml stainless steel autoclave and kept 1 h at 100°C and under hydrogen (100 atm) and then 10 h at room temperature and same pressure. After the excess hydrogen had been blown off, the apparatus was disassembled. The content was concentrated. Distillation (1 10°C, 46 mmHg) afforded methyl (S)-3-hydroxybutanoate (7.22 g, 98%, [a]p = - 50.5 c= 1.4, [a]5 6 = - 58.3 c= 1.4 in CHCI3), in 99% ee assayed as MTPA ester.
b) Hydrogenation of acrylic acid:
To the resulting reddish brown solid of RuCl2(S-4)(DMF)2 was added a solution of - aeetamidoeinnamic acid (3.6 g, 17 mmol) in degassed methanol (40 ml) and stirred for 5 min. Then the solution was transfered in to 125 ml stainless steel autoclave and kept 48h at room temperature and under hydrogen (4 atm). After the excess hydrogen had been blown off, the apparatus was disassembled. The content was concentrated to give 3.6 g crude product. A small amount from the crude product (0.05 g) was treated with excess of diazomethane (solution in ethyl ether) to yield the corresponding methyl ester for determination of the enantiomeric excess. GC analysis (25 m Chiralsil-DEX, 150° isoterm, 1 bar hydrogen, t° detector=280°C, t° colum = 280°C) of this ester shows an ee of 85.7% and no trace of the starting material. The rest of the product was dissolved in hot water (200 ml) and extracted with toluene (2X30 ml). The water was evaporated and the residue was dried under vacuum to give 3. 48 g (96%) (-)-N-acetyl- phenyl alanine, [a ]β = - 33.7 (c= 1.0 in methanol).
c) Hydrogenation of tiglic acid:
To the resulting reddish brown solid of RuCl2(S-4) (DMF)2 was added a solution of tiglic acid (1.2 g, 17 mmol) in degased methanol (30 ml) and stirred for 5 min. Then the solution was transferred to 200 ml stainless steel autoclave and kept 24h at r.t and under hydrogen (4 atm). After the excess hydrogen had been blown off, the aparatus was disassembled. The content was concentrated to give 3.6 g crude product. A small amount from the crude product (0.05 g) was treated with exess of diazomethane (solution in ethyl ether). GC analysis (25 m Chiralsil-DEX, 150° isoterm, 1 bar Hydrogen, t° detector=280°C, t° colum = 280°C) of this solution shows 90.5 % ee and no trace of the starting material. Distillation (78°C, 24 mmHg) afforded methyl (R)-2- methylbutyric acid (1.15 g, 92%, [a ]p = -17.2 (neat).
3. Enantioselective Cyciization of methyl-secone with R-Ti-1 and S-Ti-1 :
To a solution of either R-3 or S-3 (0.094g, 0.19mmol) in dry toluene (5ml) was added 4A molecular sieves (0.600 g, beads 1 mm) and AgBF4 (0.075 g, 0.39 mmol) under argon and the mixture was sonificated for 10 minutes in the dark. Then a solution of (i- PrO)2TiC.2 (0.62 ml, 0.302 M in toluene, 0.19 mmol) was added and the resulting dark red solution was stirred at room temperature in the dark for one hour. The mixture was cooled to -22°C and a solution of Methyl-secone (0.300 g, 1 mmol) in toluene (1 ml) was added dropwise. The reaction mixture was then allowed to stand at -20°C (freezer) for 3 days. The reaction mixture was quenched with 20% Na2CO3. Work up in a usual way followed by column chromatography gave 14-beta-Hydroxy-3- methoxyestra-1 ,3,5(10),8-tetraene-17-one (0.06 g, 20%, 36% ee), mp.= 162.5-163°C (EtOH); [a]D = +26.9° (c=0.2 in THF) and 3-Methoxyestra-1 , 3,5(10), 8,14-pentaene-17- one (0.17 g, 72%, 70% ee), mp.= 108.3°C (EtOH), [a]D = - 70.6° (c=0.12 in THF).

Claims

Claims
1.) Bissteroidal compounds of general formula I
in which
R-| stands for hydrogen, alkyl, acyl, fluorine, and X1 R5, where X-| stands for oxygen and sulfur and R5 can either be hydrogen, alkyl, aryl,
R2 stands for hydrogen and alkyl; the stereochemistry of C-13, C-14 and C-17 may either be a or b,
X stands for oxygen, hydroxyl, trifluormethylsulfonyloxy, or (Rg)2P, where Rg can be aryl, alkyl and cycloalkyl, R3 stands for hydrogen, alkyl, aryl, trialkylsilyl, fluorine and X2R6' where X2 stands for oxygen and sulfur and
Rg stands for hydrogen, trifluormethylsulfonyl, alkyl, cycloalkyl or aryl. R4 can either be a substituent in the 6 or 7 position of the steroid with the meaning of hydrogen, alkyl, aryl, fluorine, and X3R7, where X3 stands for oxygen, sulfur or trialkylsilyl and R7 stands for hydrogen, trifluormethylsulfonyl, alkyl or aryl, and the B-ring of the steroid contains none or two double bonds.
2.) Enantio- and diastereomeric derivatives of compounds of general formula I.
3.) Use of the compounds of claim 1 and 2 for the preparation of chiral metal complexes.
4.) Use of the compounds of claim 1 and 2 for the preparation of chiral metal complexes contaning rhodium, ruthenium, palladium, osmium, iridium, platinium, zink, titanium, aluminium, gold, lanthanoids or mixed lanthanoid - alkalli complexes .
5.) Use of the compounds of claim 1 and 2 for the preparation of chiral complexes containing rhodium, ruthenium, palladium, osmium, iridium, platinium, titanium, aluminium, gold, lanthanoids or mixed lanthanoid - alkalli complexes for all classes of asymmetric reactions, especially for the enantioselective hydrogenation of alkenes, eneamides, aldehydes or ketones, enantioselective Michael-addition reactions, enantioselective Ene-reactions, enantioselective Alkylation of aldehydes and ketones , enantioselective Diels-Alder reactions and enantioselective Hydrosilylation.
EP97954819A 1996-12-20 1997-12-18 Bissteroidal compounds and their use for the preparation of chiral complexes Withdrawn EP0946583A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP97954819A EP0946583A1 (en) 1996-12-20 1997-12-18 Bissteroidal compounds and their use for the preparation of chiral complexes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP96250295 1996-12-20
EP96250295A EP0849274A1 (en) 1996-12-20 1996-12-20 Bissteroidal compounds and their use for the preparation of chiral complexes
PCT/EP1997/007098 WO1998028322A1 (en) 1996-12-20 1997-12-18 Bissteroidal compounds and their use for the preparation of chiral complexes
EP97954819A EP0946583A1 (en) 1996-12-20 1997-12-18 Bissteroidal compounds and their use for the preparation of chiral complexes

Publications (1)

Publication Number Publication Date
EP0946583A1 true EP0946583A1 (en) 1999-10-06

Family

ID=8224794

Family Applications (2)

Application Number Title Priority Date Filing Date
EP96250295A Withdrawn EP0849274A1 (en) 1996-12-20 1996-12-20 Bissteroidal compounds and their use for the preparation of chiral complexes
EP97954819A Withdrawn EP0946583A1 (en) 1996-12-20 1997-12-18 Bissteroidal compounds and their use for the preparation of chiral complexes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP96250295A Withdrawn EP0849274A1 (en) 1996-12-20 1996-12-20 Bissteroidal compounds and their use for the preparation of chiral complexes

Country Status (5)

Country Link
EP (2) EP0849274A1 (en)
JP (1) JP2001506663A (en)
AU (1) AU6205798A (en)
CA (1) CA2275879A1 (en)
WO (1) WO1998028322A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69913412T2 (en) * 1998-04-07 2004-09-16 Firmenich S.A. Stereospecific isomerization of allylamines using chiral phospho ligands
US7223879B2 (en) 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US6307087B1 (en) 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
DK1784402T3 (en) * 2004-09-03 2011-11-14 Yuhan Corp Pyrrolo [3,2-c] pyridine derivatives as well as processes for their preparation
EP2231680B1 (en) 2007-12-12 2018-03-28 Massachusetts Institute of Technology Ligands for transition-metal-catalyzed cross-couplings, and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1140319B (en) * 1981-12-04 1986-09-24 Consiglio Nazionale Ricerche CATALYST CONTAINING CHIRAL STEROID PHOSPHINS ASYMMETRICAL CATALYTIC PRECESSES THAT USE THEM

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9828322A1 *

Also Published As

Publication number Publication date
EP0849274A1 (en) 1998-06-24
JP2001506663A (en) 2001-05-22
AU6205798A (en) 1998-07-17
WO1998028322A1 (en) 1998-07-02
CA2275879A1 (en) 1998-07-02

Similar Documents

Publication Publication Date Title
US10844088B2 (en) Process for the preparation of estetrol
AU746559B2 (en) Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
HUE028963T2 (en) Process for the production of estetrol
WO2022213805A1 (en) Method for synthesizing cholesterol by using ba as raw material
CA2835981A1 (en) Process for the production of estetrol intermediates
AU2012264602A1 (en) Process for the production of estetrol intermediates
EP0946583A1 (en) Bissteroidal compounds and their use for the preparation of chiral complexes
GB2617040A (en) Process for preparing (15alpha,16alpha,17beta)-estra-1,3,5(10)-triene-3,15,16,17-tetrol (estetrol)
CN115010638B (en) Synthesis method of Nemactetvir intermediate
US5110955A (en) Tocopherol synthesis: chromane cyclization and catalysis
EP2890705A1 (en) Process for the preparation of abiraterone or abiraterone acetate
Zhou et al. Study on the synthesis of brassinolide and related compounds III: Stereoselective synthesis of typhasterol from hyodeoxycholic acid
MXPA99004103A (en) Bissteroidal compounds and their use for the preparation of chiral complexes
JP2007516971A5 (en)
CN110655548B (en) Preparation method of 6 beta-methyl steroid compound
JP3034098B2 (en) Method for producing 2-acetyloxy-3-oxy-substituted-estrogens
EP1389623B1 (en) Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin d analogs, and other compounds
AU2002300302B2 (en) Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
WO2024008605A2 (en) Process for the preparation of [ru(oac)2(ligand)] catalysts
CN116496215A (en) Preparation method of polycyclic 3, 4-dihydro-2 (1H) -quinolinone compound
TR2023003649A2 (en) PROCESS FOR THE PREPARATION OF (15α,16α,17β)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL MONOHYDRATE (ESTETROL MONOHYDRATE)
KR100594916B1 (en) Method for Producing 4,4-Dimethyl-3?-Hydroxypregna-8,14-Diene-21-Carboxylic Acid Esters and Intermediate Products Obtained by Said Method
US6683197B1 (en) Process for the production of 4,4-dimethyl-5α-cholesta-8,14,24-trien-3β-01 and intermediate products in process (I)
Ot-Bu et al. N OBn
CN109651325A (en) A kind of synthetic method of naphtho- [1,2,3-de] chromene -2,7- cyclohexadione compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990406

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20000428

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20010217